Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

Diabetes, Obesity & Metabolism
S Del PratoS Parikh

Abstract

To assess the long-term efficacy and tolerability of dapagliflozin versus glipizide as add-on to metformin in patients with inadequately controlled type 2 diabetes. The present study was an extension of an earlier randomized, double-blind, phase III study of dapagliflozin (n = 406) vs glipizide (n = 408) to 208 weeks (4 years). Patients continued to receive their assigned medication. No statistical treatment-group comparisons were calculated. At 208 weeks, dapagliflozin compared with glipizide produced sustained reductions in glycated haemoglogin (HbA1c): -0.30% [95% confidence interval (CI), -0.51 to -0.09], in total body weight: -4.38 kg (95% CI -5.31 to -3.46) and in systolic blood pressure (SBP): -3.67 mmHg (95% CI -5.92 to -1.41). The HbA1c coefficient of failure was significantly lower for dapagliflozin than for glipizide: 0.19 (95% CI 0.12-0.25) versus 0.61 (95% CI 0.49-0.72, difference -0.42; p = 0.0001). Dapagliflozin was not associated with glomerular function deterioration, while this occurred more frequently in patients in the glipizide group. Fewer patients reported hypoglycaemia in the dapagliflozin compared with the glipizide group (5.4 vs 51.5%). Genital and urinary tract infections were more common with dapagli...Continue Reading

References

Jun 13, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·T M Wallace, D R Matthews
Apr 10, 2009·Kidney International·George L BakrisErnest M Wright
Jun 23, 2009·Expert Opinion on Drug Safety·Joanna Mitri, Osama Hamdy
Sep 15, 2012·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Yoojin Kim, Ambika R Babu
Jun 29, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Jul 16, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Feb 18, 2014·Diabetes Research and Clinical Practice·Suzanne GeerlingsShamik Parikh

❮ Previous
Next ❯

Citations

Nov 17, 2015·Expert Opinion on Pharmacotherapy·Xueying Tan, Jingbo Hu
Oct 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Dec 15, 2015·Canadian Journal of Diabetes·Pamela M Katz, Lawrence A Leiter
Mar 18, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lawrence A LeiterWilliam Canovatchel
May 15, 2016·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Giovanni CeccariniStefano Del Prato
Sep 16, 2015·Journal of Hypertension·Konstantinos P ImprialosAsterios I Karagiannis
May 26, 2016·Clinical Drug Investigation·Charalampos TzanetakosNikos Maniadakis
Jul 22, 2016·Diabetes Care·Valeriya LyssenkoStefano Del Prato
Oct 26, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M Rizzi, R Trevisan
Oct 27, 2016·Revista Española De Cardiología·Belén Dalama, Jordi Mesa
Jul 22, 2016·Diabetes Care·John P H WildingRalph A DeFronzo
Mar 16, 2017·Diabetes, Obesity & Metabolism·Daniël H van Raalte, C Bruce Verchere
Jan 13, 2018·Diabetes, Obesity & Metabolism·Itamar RazStephen D Wiviott
Jan 11, 2018·Diabetes/metabolism Research and Reviews·Angelo AvogaroIldiko Lingvay
Aug 23, 2017·Expert Review of Clinical Pharmacology·Konstantinos P ImprialosVasilios G Athyros
Oct 24, 2017·The Korean Journal of Internal Medicine·Seung-Hyun KoUNKNOWN Committee of Clinical Practice Guideline of Korean Diabetes Association
Mar 31, 2017·American Journal of Physiology. Renal Physiology·Blythe D Shepard, Jennifer L Pluznick
Dec 30, 2017·Indian Journal of Endocrinology and Metabolism·Altamash Shaikh
Dec 30, 2017·Indian Journal of Endocrinology and Metabolism·Vishal GuptaNishant Garodia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.